Basic Science News at Duke School of Medicine

Researchers at Duke University are developing a new, non-addictive way to treat chronic pain using a natural compound in the body called adenosine. Their early results show this approach could be more effective than current medications and offer a safer alternative to opioids, with fewer side effects and no risk of addiction.

She’s mapping the brain in bold new ways and the ripple effects are already reaching patients. How Nanthia Suthana’s cutting-edge brain stimulation technique is shaping treatments for post-traumatic stress disorder, Parkinson’s, obsessive-compulsive disorder, and binge eating.

As global temperatures rise, fungi are evolving to survive in warmer environments—potentially breaching the human body’s natural thermal defenses. At a Duke University symposium, scientists warned that climate change may be fueling the emergence of heat-tolerant fungal pathogens, posing a growing threat to public health.

Joseph Heitman, MD, PhD, has received the Lucille Georg Award in the basic scientist category from the International Society of Human and Animal Mycoses (ISHAM). This distinguished award recognizes lifetime achievements and outstanding contributions to the field of medical mycology.

If 98.8% of our DNA is the same as that of a chimpanzee, what changes in the remaining 1.2% make us human?

Study led by Duke School of Medicine reveals cancer’s weak spot – a protein that helps cells make energy and stops cancer from growing.

A new, high-resolution atlas of the mouse brain will increase precision in measuring changes in brain structure and make it easier to share results for scientists working to understand neurological diseases such as Alzheimer's.

A Duke University School of Medicine team reimagines a sci-fi classic as real-world biotech that can speed up biological research.

An epic collaboration between neuroscientists at Duke and six other institutions has yielded an AI tool that paves the way for new approaches to treating neurological disorders.

New strategy could change how we design drugs—especially the large and polar ones that were once too big to work.